First Horizon Advisors’s Celldex Therapeutics CLDX Stock Holding History

First Horizon Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$24.3K	Buy	1,195 +862	+259%	+$16.8K	﹤0.01%	1337
2025 Q1	$6.04K	Hold	333	–	–	﹤0.01%	1763
2024 Q4	$8.41K	Hold	333	–	–	﹤0.01%	1657
2024 Q3	$11.3K	Hold	333	–	–	﹤0.01%	1569
2024 Q2	$12.3K	Hold	333	–	–	﹤0.01%	1447
2024 Q1	$14K	Hold	333	–	–	﹤0.01%	1469
2023 Q4	$13.2K	Hold	333	–	–	﹤0.01%	1488
2023 Q3	$9.16K	Hold	333	–	–	﹤0.01%	1544
2023 Q2	$11.3K	Hold	333	–	–	﹤0.01%	1496
2023 Q1	$12K	Hold	333	–	–	﹤0.01%	1484
2022 Q4	$14.8K	Hold	333	–	–	﹤0.01%	1376
2022 Q3	$9K	Hold	333	–	–	﹤0.01%	1539
2022 Q2	$9K	Hold	333	–	–	﹤0.01%	1615
2022 Q1	$11K	Hold	333	–	–	﹤0.01%	1069
2021 Q4	$13K	Hold	333	–	–	﹤0.01%	1434
2021 Q3	$18K	Buy	+333	New	+$15.6K	﹤0.01%	1315

Other funds holding CLDX

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Horizon Advisors's CLDX Position: Q2 2025 in Review

First Horizon Advisors increased its Celldex Therapeutics (CLDX) stake by 259% in Q2 2025, buying an estimated $16.8K and bringing the position to 1,195 shares worth $24.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1337.

First Horizon Advisors first reported a position in CLDX in Q3 2021 and has held it in 16 quarters since. 180 funds tracked by Wall St. Rank hold CLDX as of Q2 2025.

First Horizon Advisors held 1,195 shares of Celldex Therapeutics worth $24.3K as of Q2 2025.
First Horizon Advisors bought 862 Celldex Therapeutics shares in Q2 2025, an estimated $16.8K.
Celldex Therapeutics made up ﹤0.01% of First Horizon Advisors's portfolio in Q2 2025, its #1337 holding.
First Horizon Advisors first reported a position in Celldex Therapeutics in Q3 2021 and has held it in 16 quarters since.
180 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2025.

Based on First Horizon Advisors's 13F filing for Q2 2025, filed 6 Aug 2025.